Taxonomy of mucoactive medications

Therapy for Mucus-Clearance Disorders

Volumn , Issue , 2004, Pages 129-145

  Rubin, Bruce K ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34047144270     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. King M, Rubin BK. Mucus physiology and pathophysiology: therapeutic aspects. In: Derenne JP, Similowski T, Whitelaw WA. eds. Chronic Obstructive Lung Disease. New York: Marcel Dekker, 1996:391-411.
2. Wanner A, Salathé M, O’Riordan TG. Mucociliary clearance in the airways. Am J RespirCrit Care Med 1996; 154:1868-1902.
3. King M. Rubin BK. Mucus rheology: relationship with transport. In: Takishima T, ed. Airway Secretion: Physiological Bases for the Control of Mucus Hypersecretion. New York: Marcel Dekker. 1994:283-314.
4. Rubin BK, Tomkiewicz RP, King M. Mucoactive agents: old and new. In: Wilmott RW, ed. The Pediatric Lung. Basel: Birkhauser, 1997:155-179.
5. Rubin BK, MacLeod PM, Sturgess JM, King M. Recurrent respiratory infections in a child with fucosidosis: is the mucus too thin for effective transport? Ped Pul-monol 1991; 10:304-309.
6. Iotti GA, Olivei MC, Palo A, et al. Unfavorable mechanical effects of heat and moisture exchangers in ventilated patients. Intensive Care Med 1997; 23:399-405.
7. Shim C, King M, Williams MJ. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987; 92:679-682.
8. Marchette LC. Marchette BE, Abraham WM, Wanner A. The effect of systemic hydration on normal and impaired mucociliary function. Pediatr Pulmonol 1985; 1: 107-111.
9. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable bronchitis. Chest 1996; 109:348-352.
10. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996; 21: 77-83.
11. Daviskas E, Anderson SD, Brannan JD, Chan HK. Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 1997; 10: 2449-2454.
12. Wills PJ, Hall RL, Chan WM. Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9-13.
13. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229-236.
14. Jiang Q, Engelhardl JF. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Eur J Hum Gene 1998; 6:12-31.
15. Dorin JR, Farley R, Webb S, et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther 1996; 3:797-801.
16. Arispe N, Ma J, Jacobson KA, Pollard HB. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxan-thine (CPX) and l,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1998; 273: 5727-5734.
17. Weinreich F, Wood PG, Riordan JR, Nagel G. Direct action of genistein on CFTR. Pflugers Arch 1997; 434:484-491.
18. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157:484-490.
19. Haws CM, Nepomuceno I, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H, Wine JJ. AF508-CFTR channels: Kinetics, activation by forskolin. and potentiation by xanthines. Am J Physiol 1996; 270:C1544-C1555.
20. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1:117-125.
21. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322:1189-1194.
22. Graham A, Hashani A, Alton EW, Martin GP, Marriott C, Hodson ME. Clarke SW, Geddes DM. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6:1243-1248.
23. Stutts MJ, Fitz JG, Paradiso AM, Boucher RC. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP. Am J Physiol 1994; 267: C1442-C1451.
24. Bennett WD, Olivier KN, Zeman KL, Hohneker KH. Boucher RC, Knowles MR. Effect of aerosolized uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis patients. Am J Respir Crit Care Med 1996; 153:1796-1801.
25. Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8:15-25.
26. Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 1998; 9:2207-2222.
27. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase 1 study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7:1145-1159.
28. Goldman MJ, Lee PS, Yang JS, Wilson JM. Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 1997; 8:2261-2268.
29. McDonald RJ, Liggitt HD, Roche L, Nguyen HT. Pearlman, R, Raabe OG, Bussey LB, Gorman CM. Aerosol delivery of lipid:DNA complexes to lungs of rhesus monkeys. Pharm Res 1998; 15:671-679.
30. Puchelle E, Zahm JM, Girard F, Bertrand A, Polu JM, Aug F, Sadoul P. Mucociliary transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis. Eur J Respir Dis 1980; 61:254-264.
31. Dasgupta B. King M. Molecular basis for mucolytic therapy. Can Respir J 1995; 2:223-230.
32. Millar AB, Pavia D. Agnew JE. Lopez-Vidriero MT. Lauque D, Clarke SW. Effect of oral N-acety Icy steine on mucus clearance. Br J Dis Chest 1985; 79:262-266.
33. Thomson ML, Pavia D, Jones CJ. McQuiston TA. No demonstrable effect of S-carboxymethylcysteine on clearance of secretions from human lung. Thorax 1975; 30:669-673.
34. Tomkiewicz RP. App EM. De Sanctis GT, Coffincr M, Maes P, Rubin BK, King M. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcys-teine: airway epithelial function and mucus changes in dog. Pulm Pharmacol 1995; 8:259-265.
35. Rose MC, Gendler SJ. Airway mucin genes and gene products. In: Rogers DF, Lethem MI, eds. Airway Mucus: Basic Mechanisms and Clinical Perspectives. Basel: Birkhäuser. 1997:41-66.
36. Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med 1998; 157: 710-714.
37. Tomkiewicz RP, Kishioka C, Freeman J, Rubin BK. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G. ed. Cilia, Mucus and Mucociliary Interactions. New York: Marcel Dekker. 1998:333-341.
38. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of domase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996; 110:889-895.
39. Bone RC, Fuchs H. Fox NL. Meinen L, Sanders C, Hyzy R, Thompson N, Fiel S. The chronic obstructive pulmonary disease mortality endpoint trial. Chest 1995;108:R.
40. Wills PJ, Wodehouse T, Corkery K, Malion K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996; 154:413-417.
41. Vasconcellos CA, Allen PG, Wohl M, Drazen JM, Janmey PA. Reduction in sputum viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-971.
42. Rubin BK. Emerging therapies for cystic fibrosis lung disease. Chest 1999; 115: 1120-1126.
43. Rubin BK. Surface properties of respiratory secretions: relationship to mucus transport. In: Baum G, ed. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker, 1998:317-324.
44. Agarwal M, King M, Rubin BK, Shukla JB. Mucus transport in a miniaturized simulated cough machine: Effect of constriction and serous layer simulant. Biorheology 1989; 26:977-988.
45. Rubin BK. Tracheomalacia as a cause of respiratory compromise in infants. Clin Pulm Med 1999; 6:1-4.
46. De Sanctis GT, Tomkiewicz RP, Rubin BK, Schiirch S, King M. Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 1994; 7:1616-1621.
47. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G. Pattishall EN, Barret J, Engle M, Perret K. Rubin BK. Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial. JAMA1997; 278:1426-1431.
48. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92:618-620.
49. Lopez-Vidriero MT, Costello J, Clark TJ, Das I. Keal EE, Reid L. Effect of atropine on sputum production. Thorax 1975; 30:543-547.
50. King M, Cohen C, Viires N. Influence of vagal tone on rheology and transportability of canine tracheal mucus. Am Rev Respir Dis 1979; 120:1215-1219.
51. Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986; 81:23-27.
52. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994; 49:545-548.
53. Bames PJ. Muscarinic receptor subtypes: implications for therapy. Agents Actions Suppl 1993; 43:243-252.
54. Moretti M, Giannico G, Marchioni CF, Bisetti A. Effects of méthylprednisolone on sputum biochemical components in asthmatic bronchitis. Eur J Respir Dis 1984; 65:365-370.
55. Marom Z, Shelhamer J, Ailing D, Kaliner M. The effects of corticosteroids on mucous glycoprotein secretion from human airways in vitro. Am Rev Respir Dis1984; 129:62-65.
56. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic fibrosis foundation prednisone trial group. J Pediatr 1995; 126:515-523.
57. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-854.
58. Tamaoki J, Chiyotani A. Kobayashi K, Sakai N, Kanemura T, Takizawa T. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992; 145:548-552.
59. Aronoff SC. Quinn FJ Jr., Carpenter LS, Novick WJ Jr. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatrics 1994; 125:992-997.
60. Ghio AJ, Marshall BC, Diaz JL, Hasegawa T. Samuelson W. Povia D. Kennedy TP, Piantadosi CA. Tyloxapol inhibits NF-kB and cytokine release, scavenges HOCL, and reduces viscosity of cystic fibrosis sputum. Am J Respir Crit Care Med1996; 154:783-788.
61. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macro-lides. Am J Physiol 1997; 272:L15-L19.
62. Suez D. Szefler SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986; 77:330-334.
63. Tamaoki J. Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39:1688-1690.
64. Suga T, Sugiyama Y, Fujii T, Kitamura S. Bronchoalveolar carcinoma with bronch-orrhoea treated with erythromycin. Eur Respir J 1994; 7:2249-2251.
65. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155:2018-2023.
66. Tamaoki J, Sakai N, Tagaya E, Konno K. Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea. Antimicrob Agents Chemother 1994; 38:1641-1643.
67. Khair OA. Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8:1451-1457.